Muutke küpsiste eelistusi

E-raamat: Ketamine: From Abused Drug to Rapid-Acting Antidepressant

Edited by , Edited by , Edited by
  • Formaat: PDF+DRM
  • Ilmumisaeg: 05-Mar-2020
  • Kirjastus: Springer Verlag, Singapore
  • Keel: eng
  • ISBN-13: 9789811529023
  • Formaat - PDF+DRM
  • Hind: 172,28 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Formaat: PDF+DRM
  • Ilmumisaeg: 05-Mar-2020
  • Kirjastus: Springer Verlag, Singapore
  • Keel: eng
  • ISBN-13: 9789811529023

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

This book presents the latest data from basic research and clinical trials supporting the effectiveness of ketamine as a treatment for depression, bipolar disorder, and suicidal behavior, setting these positive findings within the context of the serious problem of ketamine abuse. The first part of the book focuses on the evidence regarding ketamine abuse, with specific reference to Asian countries, and discusses countermeasures and complication management. It then addresses the mechanisms underlying the antidepressant and side effects of ketamine, which have remained elusive, describing and discussing important new research findings. Further, it explains insights gained from whole brain imaging in rodents and from behavioral pharmacology, and presents evidence regarding the role of gut microbiota, the NMDA receptor GluN2D subunit, and the lateral habenula in the actions of ketamine. These advances form the basis for the safer use of ketamine in patients with treatment-resistant depression and are expected to lead to the development of new antidepressants.

Ketamine Abuse: Past and Present
1(14)
Ming-Chyi Huang
Shih-Ku Lin
Brain Imaging of Ketamine Abusers
15(18)
Yanhui Liao
Wei Hao
Management of Complications of Ketamine Abuse
33(14)
Steffi K. K. Yuen
Anthony C. F. Ng
Site of Ketamine Action on the NMDA Receptor
47(22)
Hisashi Mori
Synaptic Modulation in the Effect of Ketamine
69(20)
Daisuke Okada
Behavioral Pharmacology of Ketamine: An Overview of Preclinical Studies
89(16)
Naoyuki Hironaka
Antidepressant Actions of Ketamine and Its Two Enantiomers
105(22)
Lijia Chang
Yan Wei
Kenji Hashimoto
The Role of Gut Microbiota in the Antidepressant Effects of Ketamine
127(16)
Yue Wang
Xiaolin Xu
Ailin Luo
Chun Yang
Effects of Ketamine on Pain and Depression Comorbidity
143(14)
Xiao-Hui Tang
Jian-Jun Yang
Distinct Roles of NMDA Receptor GluN2 Subunits in the Effects of Ketamine and Its Enantiomers
157(18)
Soichiro Ide
Kazutaka Ikeda
Effects of Adjunctive Ketamine Intravenous Infusion in Taiwanese Patients with Treatment-Resistant Depression: Antidepression, Antisuicidality, BDNF Val66Met, and Brain Imaging
175
Mu-Hong Chen
Tung-Ping Su
Kenji Hashimoto, Chiba University, Chiba, Japan Dr. Hashimoto is a Professor and Vice-Director of the Center for Forensic Mental Health at Chiba University. He holds a PhD from the Faculty of Pharmaceutical Sciences at Kyushu University. After working at Fukuyama University, NIH/NIDA (Baltimore, MD) and a pharmaceutical company, he moved to Chiba University Graduate School of Medicine, where he works on the development of novel therapeutic drugs for psychiatric and neurological disorders. Dr. Hashimoto has published more than 500 articles in PubMed listed publications. 





Soichiro Ide, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan Dr. Ide is a Chief Researcher in the Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science. He holds a PhD from the Graduate School and Faculty of Pharmaceutical Sciences at Kyoto University. Dr. Ide taught and undertook research research at Hiroshima International University and Hokkaido University, before moving to his current laboratory. He is currently conducting neuropsychopharmacological research using behavioral pharmacological techniques on topics such as pain, depression, and stress. Dr. Ide has published 60 papers in PubMed listed publications.





Kazutaka Ikeda, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan Dr. Ikeda is Project Leader of the Addictive Substance Project and Chair of the Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science. He graduated from the Faculty of Engineering at The University of Tokyo, and holds a Masters degree from Osaka University and a PhD from Niigata University. Dr. Ikeda has worked at RIKEN, Tokyo Metropolitan Institute of Psychiatry, and was President of the Japanese Society of Neuropsychopharmacology and of the Asian College of Neuropsychopharmacology. His research focuses on neuropsychopharmacology, especially for addiction, pain, neurodevelopmental disorders, schizophrenia and depression. He has published more than 180 articles in PubMed listed publications.